Bihua Chen
CIK 1599214 · Chairperson and CEO · last filed 2026-07-06
Bihua Chen is a Chairperson and CEO who has filed 45 SEC Form 4 insider transactions across 22 companies since 2016. The most recent filing, for BBOT, was dated Jul 6, 2026. Across all open-market trades the lifetime net is +$446.8M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $604.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$604.43M
22
45
$446.78M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BBOT | Director | 1,905,046 | $8.59 | $16.36M | $0 | 3 | 2026-07-06 |
| HLXC | Chairperson and CEO | 497,500 | $10.56 | $5.25M | $16.00M | 2 | 2026-01-28 |
| EYPT | 10%+ Owner | 8,265,000 | $11.96 | $98.85M | $234.19M | 5 | 2025-12-08 |
| MLTX | 10%+ Owner | 1,994,173 | $18.71 | $37.31M | -$154.25M | 6 | 2025-10-01 |
| OKUR | 0 | $3.95 | $0 | -$20.18M | 1 | 2025-05-19 | |
| AARD | 800,189 | $6.42 | $5.14M | $6.00M | 1 | 2025-02-19 | |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | CEO and Chairperson | — | $9.90 | — | $0 | 1 | 2025-02-10 |
| DRUG | 10%+ Owner | 1,059,331 | $71.96 | $76.23M | $17.70M | 2 | 2024-11-06 |
| IMRX | 10%+ Owner | 3,294,173 | $4.24 | $13.97M | -$15.64M | 2 | 2024-04-03 |
| CRBP | 10%+ Owner | 1,475,000 | $9.09 | $13.40M | $70.09M | 2 | 2024-02-06 |
| Ambrx Biopharma Inc. (AMAM) Delisted | 10%+ Owner | 68,714,590 | $28.00 | $1.92B | $78.50M | 1 | 2023-09-19 |
| BMEA | Director | 3,570,872 | $1.25 | $4.46M | $0 | 1 | 2023-06-16 |
| ERAS | Director | 10,813,246 | $18.16 | $196.37M | $8.67M | 3 | 2022-12-21 |
| PYXS | Director | 668,854 | $2.91 | $1.95M | $28.80M | 1 | 2021-10-15 |
| BCAB | Director | 45,841 | $3.53 | $161.8K | $57.60M | 1 | 2020-12-22 |
| OLMA | Director | 3,270,544 | $11.62 | $38.00M | $40.38M | 1 | 2020-11-23 |
| MoonLake Immunotherapeutics (HLXA) Delisted | CEO and Chairman | 430,000 | $13.25 | $5.70M | $4.30M | 1 | 2020-10-22 |
| RNA | Director | 2,214,545 | $11.49 | $25.45M | $21.60M | 1 | 2020-06-18 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 3,122,367 | $76.01 | $237.33M | $14.40M | 3 | 2019-08-12 |
| Axonics, Inc. (AXNX) Delisted | Director | 599,999 | $70.98 | $42.59M | $8.00M | 1 | 2018-11-02 |
| KNSA | Director | 900,443 | $79.44 | $71.53M | $5.00M | 1 | 2018-05-31 |
| KINETA, INC./DE (PTI) Delisted | Director | 189,136 | — | — | $25.62M | 4 | 2016-12-14 |
Recent Filings
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | BBOT | Other (J) | — | $0 | EDGAR |
| 2026-06-18 | BBOT | Grant (A) | — | $0 | EDGAR |
| 2026-01-28 | HLXC | Mixed | +2,595,000 | $25.95M | EDGAR |
| 2026-01-26 | HLXC | Mixed | +995,000 | $9.95M | EDGAR |
| 2025-12-08 | EYPT | Sell (S) | −180,000 | -$2.83M | EDGAR |
| 2025-10-01 | MLTX | Sell (S) | −38,999,868 | -$281.21M | EDGAR |
| 2025-08-13 | BBOT | Mixed | +14,969,594 | $75.00M | EDGAR |
| 2025-05-19 | OKUR | Sell (S) | −10,880,634 | -$20.18M | EDGAR |
| 2025-02-19 | AARD | Mixed | +1,975,378 | $6.00M | EDGAR |
| 2025-02-10 | BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | Other (J) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.